459
Views
12
CrossRef citations to date
0
Altmetric
Review

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations

, , , &
Pages 51-55 | Received 04 Aug 2016, Accepted 29 Nov 2016, Published online: 16 Dec 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Hua Duan, Yanmei Peng, Huijuan Cui, Yuqin Qiu, Qiang Li, Jingyi Zhang, Wen Shen, Chenyao Sun & Chufan Luo. (2018) Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report. OncoTargets and Therapy 11, pages 2303-2309.
Read now

Articles from other publishers (11)

Chang Liu, Zhenxing Wang, Qian Liu, Guangyao Wu, Chunhong Chu, Lanxin Li, Lei An & Shaofeng Duan. (2022) Sensitivity analysis of EGFR L861Q mutation to six tyrosine kinase inhibitors. Clinical and Translational Oncology 24:10, pages 1975-1985.
Crossref
Elisabetta Grillo, Michela Corsini, Cosetta Ravelli, Margherita di Somma, Luca Zammataro, Eugenio Monti, Marco Presta & Stefania Mitola. (2021) A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. Cancer Letters 496, pages 84-92.
Crossref
Li Lv, Zhichao Liu, Yang Liu, Wenhui Zhang, Lifeng Jiang, Tingting Li, Xinyan Lu, Xuefen Lei, Wenhua Liang & Jie Lin. (2020) Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis. Frontiers in Oncology 10.
Crossref
Evangelia Katsoulakis, Jill E. Duffy, Bradley Hintze, Neil L. Spector & Michael J. Kelley. (2020) Comparison of Annotation Services for Next-Generation Sequencing in a Large-Scale Precision Oncology Program. JCO Precision Oncology:4, pages 212-221.
Crossref
Teresa Moran, Alvaro Taus, Edurne Arriola, Carlos Aguado, Manuel Dómine, Ana Gómez Rueda, Antonio Calles, Susana Cedrés, Nuria Viñolas, Dolores Isla, Ramón Palmero, María Sereno, Victor Diaz, Oscar Juan, Raquel Marsé, Paloma Martín Martorell, José Miguel Sánchez Torres, Georgia Anguera, Joaquim Bosch, Luis Cabezón, Silvia Catot, Alex Martinez, Silvia Muñoz & Inmaculada Ramos. (2020) Clinical Activity of Afatinib in Patients With Non–Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Clinical Lung Cancer 21:5, pages 428-436.e2.
Crossref
Yangyang Cai, Yizhuo Wang, Jingnan Sun, Xu Wang, Yinghui Xu, Chao Sun, Ye Guo, Mengyao Sun & Kewei Ma. (2020) Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report. Journal of International Medical Research 48:6, pages 030006052092879.
Crossref
Gil Alterovitz, Bret Heale, James Jones, David Kreda, Fan Lin, Lei Liu, Xin Liu, Kenneth D. Mandl, David W. Poloway, Rachel Ramoni, Alex Wagner & Jeremy L. Warner. (2020) FHIR Genomics: enabling standardization for precision medicine use cases. npj Genomic Medicine 5:1.
Crossref
Ting-Hui Wu, Emily Han-Chung Hsiue & James Chih-Hsin Yang. (2019) Opportunities of circulating tumor DNA in lung cancer. Cancer Treatment Reviews 78, pages 31-41.
Crossref
Pragya Misra & Shailza Singh. (2019) Role of cytokines in combinatorial immunotherapeutics of non‐small cell lung cancer through systems perspective. Cancer Medicine 8:5, pages 1976-1995.
Crossref
Ting-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, Chia-Chi Lin, Wei-Yu Liao, Chao-Chi Ho, Jin-Yuan Shih, Chong-Jen Yu & James Chih-Hsin Yang. (2018) Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non–Small-cell Lung Cancer Patients. Clinical Lung Cancer 19:3, pages e361-e372.
Crossref
Pragya Misra & Shailza Singh. (2018) Role of Cytokines in Combinatorial Immunotherapeutics of Non-Small Cell Lung Cancer Through Systems Perspective. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.